P3 Health Partners Inc. 8-K

What Happened
P3 Health Partners Inc. (PIII) filed an 8-K on May 15, 2026 announcing that it completed a debt-for-equity transaction and initial preferred unit sales intended to cure a Nasdaq listing deficiency. After a notice from Nasdaq (Nov 28, 2025) for failing to meet Listing Rule 5550(b)(1) (minimum $2.5M stockholders’ equity) and an extension to May 20, 2026, the company entered a Debt Exchange Agreement on April 27, 2026 with affiliates of Chicago Pacific Founders (CPF) and sold Units under a Securities Purchase Agreement. The company believes these actions have restored compliance and provided an unaudited pro forma balance sheet (Exhibit 99.1) based on its March 31, 2026 10-Q.

Key Details

• Approximately $252,479,967 of outstanding promissory notes (principal, accrued interest and fees) was exchanged for preferred stock on April 27, 2026.
• The preferred issued in the Debt Exchange is non-convertible, has no voting or preemptive rights, is not registered or listed, and has a stated value of $100 per share.
• The company entered a Purchase Agreement to issue up to $70.0M of Units (Series D 19.5% Cumulative Preferred Stock plus warrants); $30.0M of Units had been sold as of this 8-K filing.
• The pro forma condensed consolidated balance sheet (Exhibit 99.1) is presented on a March 31, 2026 basis and the company states it now satisfies the Nasdaq stockholders’ equity requirement; Nasdaq will continue to monitor compliance.

Why It Matters
For investors, these transactions materially change P3’s capital structure by converting a large portion of debt to non-convertible preferred equity and raising additional preferred units, which the company says restores the minimum stockholders’ equity required by Nasdaq. That reduces immediate delisting risk tied to the equity deficiency, but Nasdaq will still review the company’s next periodic report—continued compliance is required to avoid potential delisting.